Characteristics of atheromatosis in the prediabetes stage: a cross-sectional investigation of the Ilervas project by Sánchez Peña, Enric et al.
Sánchez et al. Cardiovasc Diabetol          (2019) 18:154  
https://doi.org/10.1186/s12933-019-0962-6
ORIGINAL INVESTIGATION
Characteristics of atheromatosis 
in the prediabetes stage: a cross-sectional 
investigation of the ILERVAS project
Enric Sánchez1†, Àngels Betriu2†, Carolina López‑Cano1, Marta Hernández1, Elvira Fernández2, 
Francisco Purroy3, Marcelino Bermúdez‑López2, Cristina Farràs‑Sallés4,5, Silvia Barril6,7, Reinald Pamplona8, 
Ferran Rius1, Cristina Hernández9,10, Rafael Simó9,10* and Albert Lecube1,10*  on behalf of the ILERVAS project 
collaborators
Abstract 
Background: Prediabetes has recently been associated with subclinical atheromatous disease in the middle‑aged 
population. Our aim was to characterize atheromatous plaque burden by the number of affected territories and the 
total plaque area in the prediabetes stage.
Methods: Atheromatous plaque burden (quantity of plaques and total plaque area) was assessed in 12 territories 
from the carotid and femoral regions using ultrasonography in 6688 non‑diabetic middle‑aged subjects without car‑
diovascular disease. Prediabetes was defined by glycosylated hemoglobin (HbA1c) between 5.7 and 6.4% according 
to the American Diabetes Association guidelines.
Results: Prediabetes was diagnosed in 33.9% (n = 2269) of the ILERVAS participants. Subjects with prediabetes pre‑
sented a higher prevalence of subclinical atheromatous disease than participants with HbA1c < 5.7% (70.4 vs. 67.5%, 
p = 0.017). In the population with prediabetes this was observed at the level of the carotid territory (p < 0.001), but not 
in the femoral arteries. Participants in the prediabetes stage also presented a significantly higher number of affected 
territories (2 [1;3] vs. 1 [0;3], p = 0.002), with a positive correlation between HbA1c levels and the number of affected 
territories (r = 0.068, p < 0.001). However, atheromatosis was only significantly (p = 0.016) magnified by prediabetes in 
those subjects with 3 or more cardiovascular risk factors. The multivariable logistic regression model showed that the 
well‑established cardiovascular risk factors together with HbA1c were independently associated with the presence of 
atheromatous disease in participants with prediabetes. When males and females were analyzed separately, we found 
that only men with prediabetes presented both carotid and femoral atherosclerosis, as well as an increase of total 
plaque area in comparison with non‑prediabetic subjects.
Conclusions: The prediabetes stage is accompanied by an increased subclinical atheromatous disease only in the 
presence of other cardiovascular risk factors. Prediabetes modulates the atherogenic effect of cardiovascular risk fac‑
tors in terms of distribution and total plaque area in a sex‑dependent manner.
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Background
The International Diabetes Federation has estimated that 
in 2017 there were 451 million individuals with diabetes 
plus 374 million people with impaired glucose tolerance 
worldwide, with a total expenditure of USD 850  billion 
[1]. Cardiovascular (CV) disease is the main comorbidity 
of diabetes and is estimated to affect 32.2% of all subjects 
and is responsible for 27% of the total cost of treating dia-
betes [2, 3]. At diagnosis, many patients with type 2 dia-
betes have one or more additional classical risk factors for 
macrovascular disease and many have evidence of overt 
atherosclerosis [4]. In addition, all phases in the patho-
physiology of plaque formation are enhanced in type 
2 diabetes, contributing to an accelerated process [5]. 
However, symptoms are not always present, and the term 
“unrecognized diabetic cardiac impairment” has been 
proposed for individuals that develop CV disease without 
the classic angina-related or heart failure symptoms [6]. 
Finally, compared with subjects without diabetes, ather-
omatous disease in diabetes has special characteristics, 
such as its being more extensive, and affecting multiple 
and more peripheral blood vessels, that makes it more 
serious and aggressive [7].
The problem increases when we consider that many 
of the atherogenic risk factors are already present in the 
prediabetic stage, years before the diagnosis of type 2 dia-
betes [8]. The milieu that favors CV disease in the predia-
betes stage is more than hyperglycemia in the nondiabetic 
range and the effect of insulin resistance in the vessel 
walls. It includes a cluster of different metabolic changes 
that favors the development of atheromatous disease, 
such as low-grade chronic inflammation, endothelial 
vasodilator and fibrinolytic dysfunction, and an athero-
genic lipoprotein profile [9, 10]. In this way, prospective 
cohort studies have shown how prediabetes [defined as 
impaired fasting glucose, impaired glucose tolerance or 
raised glycated hemoglobin (HbA1c)] is associated with 
an increased risk of composite CV disease, coronary 
heart disease and stroke compared with normoglycemia 
[11]. Similarly, during an 8-years period and compared 
to individual with persistent normoglycemia, those who 
shifted from normoglycemia to impaired fasting glu-
cose had a significant increased risk of all-cause mortal-
ity [12]. Remarkably, the health risk increases in subjects 
with values as low as 5.6 mmol/L for fasting glucose con-
centration or 39 mmol/mol for HbA1c. On this basis, it 
is of clinical relevance to evaluate the characteristics of 
subclinical atheromatous disease in the prediabetes stage 
[11].
To shed light on this issue, we performed a cross-sec-
tional study in order to characterize atheromatous plaque 
burden by the number of affected territories and the total 
plaque area in the prediabetes stage.
Methods
Study population, metabolic status and the selection 
of patients
A total of 6809 subjects were enrolled between January 
2015 and December 2017 from 30 primary health care 
centers in Lleida, Spain. The ILERVAS project is an ongo-
ing clinical trial dealing with subclinical atheromatous 
disease (ClinicalTrials.gov Identifier: NCT03228459) 
[13]. The inclusion criteria were as follows: age 
45–70 years, no history of cardiovascular disease, and at 
least one cardiovascular risk factor (dyslipidemia, blood 
hypertension, obesity, smoking habit or a first degree 
relative with premature (< 55  years old in men, < 65 in 
women) cardiovascular disease (myocardial infarction, 
stroke and peripheral arterial disease). The exclusion cri-
teria were any type of diabetes, chronic kidney disease, 
active neoplasia, a life expectancy of less than 18 months 
and pregnancy.
According to the current American Diabetes Asso-
ciation guidelines, prediabetes was defined as an HbA1c 
between 39 and 47 mmol/mol (5.7 to 6.4%) and normal 
glucose metabolism as an HbA1c < 39 mmol/mol (< 5.7%) 
[14]. The HbA1c test was performed in capillary blood 
using a point-of-care device [Cobas B  101®, Roche Diag-
nostics S.L., Sant Cugat del Vallès, Spain], based on a 
latex agglutination inhibition immunoassay procedure 
that meets the generally accepted performance criteria 
for HbA1c [15]. A total of 121 participants with previ-
ously undiagnosed type 2 diabetes [(HbA1c ≥ 48.0 mmol/
mol (≥ 6.5%)] were excluded from the investigation that 
was finally performed in 6688 subjects.
Clinical data regarding the cardiovascular risk factors 
were obtained from an electronic database (Informa-
tion System for the Development of Research in Primary 
Care, SIDIAP) that comprises anonymized and longitu-
dinal information from the Catalan Health Institute. The 
prevalence of dyslipidemia was obtained from patients 
who during the study period had a diagnostic code for 
disorders of lipoprotein metabolism according to of the 
International Classification of Diseases codes. The inci-
dence of blood hypertension was obtained from subjects 
who had an identification code for hypertensive diseases. 
Obesity was defined by a body mass index (BMI) ≥ 30 kg/
m2.
The prescribed antihypertensive, lipid-lowering and 
antithrombotic treatments were extracted from pre-
scription- and pharmacy-invoicing databases provided 
by the Catalan Health Service, which are incorporated 
yearly into the SIDIAP database. Antihypertensive 
medication agents included ACE inhibitors, diuretics, 
ARA II, beta-blockers, calcium antagonists and other 
antihypertensives. Lipid-lowering drugs included 
statins, fibrates, ezetimibe and omega-3 fatty acids. 
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Antithrombotic treatment consisted of the use of anti-
coagulant or antiplatelet agents.
Evaluation of clinical variables
Height and body weight were measured without shoes 
and in light clothing, and the body mass index (BMI) 
was obtained. A non-stretchable tape with a preci-
sion of 0.1 cm was used to assess waist circumference. 
According to a specified protocol, total cholesterol 
(mg/dl) levels were assessed in all participants from a 
non-fasting dried capillary blood test (fingertip punc-
ture) using the  REFLOTRON® Plus system (Roche 
Diagnostics, GmbH, Germany) [13]. Quantification of 
the entire lipid profile (HDL cholesterol, LDL choles-
terol and triglycerides) was evaluated only in subjects 
in which total cholesterol was ≥ 200 mg/dL after fasting 
for 6 h or where total cholesterol ≥ 250 mg/dL regard-
less of fasting hours.
Blood pressure was measured in triplicate, after 5 min’ 
rest using an automated device [Omron M6 Comfort 
HEM-7221-E (Omron Healthcare, Kyoto, Japan)] at 
2-min intervals, and the mean of the last 2 was calcu-
lated. The smoking habit (non-smoker, current or former 
smoker) was also documented. Smokers who stopped 
smoking ≥ 1  year prior to recruitment were considered 
former smokers.
Assessment of atheromatous plaque burden by ultrasound 
study
Bilateral carotid (common, bifurcation, internal and 
external arteries) and femoral (common and superficial 
arteries) areas were explored. The pictures were obtained 
by qualified sonographers using an ultrasonic Doppler 
Ultrasound Vivid-I (General Electric Healthcare, Wauke-
sha, WI, USA) equipped with probe broadband linear 
12L-RS that works at frequencies between 5 and 13 MHz. 
Standardized and validated scanning and reading pro-
tocols were used to decrease inter-operator variability 
and type 2 errors [16]. To measure intra and inter rater 
absolute agreement, Fleiss’ kappa for plaque presence 
and intraclass correlation coefficient for plaque area were 
obtained (Additional file  1: Table  S1). The readers were 
unaware of the patients’ clinical histories.
Subclinical atheromatosis was defined as the pres-
ence of any plaque in the twelve assessed areas [17]. A 
plaque was well-defined as a focal intima-media thick-
ness ≥ 1.5  mm protuberant in the lumen [18]. Subjects 
were categorized as having focal (1 territory), intermedi-
ate (2 to 3 territories), or generalized (4 to 12 territories) 
atheromatous disease. All plaques were measured, and 
the total plaque area  (cm2) was assessed [19].
Statistical analysis
Owing the non-normal distribution of the data detected 
by the Shapiro–Wilk test, quantitative data was expressed 
as the median [interquartile range]. Comparisons 
between the prediabetes and non-prediabetes groups 
were made using the Mann–Whitney U test for quantita-
tive variables, and the Pearson’s Chi-squared test for cat-
egorical variables. The relationship between continuous 
variables was assessed by the Spearman correlation test.
A multivariable logistic regression model for the pres-
ence of subclinical atheromatous disease for the devel-
opment cohort was performed including the following 
confounding elements: sex, age, HbA1c, total cholesterol, 
systolic blood pressure, the BMI, waist circumference, 
smoking habit and medical treatments. The calibration 
and discrimination of the multivariable logistic regres-
sion model were evaluated using the goodness of fit Hos-
mer–Lemeshow test and the area under the Receiver 
Operating Characteristic curve, correspondingly. All “p” 
values were based on a two-sided test of statistical sig-
nificance, and significance was accepted at the level of 
p < 0.050. All statistical analyses were performed using 
SSPS statistical package (IBM SPSS Statistics for Win-
dows, Version 25.0. Armonk, NY, USA).
Results
From the baseline sample of 6809 subjects, prediabetes 
was diagnosed in 33.3% (n = 2269) of the subjects. The 
main clinical and metabolic data according to the HbA1c 
values are displayed in Table 1. Participants with predia-
betes were older and presented a higher ratio of women 
and classical CV risk factors such as dyslipidemia, 
hypertension and obesity in comparison with the con-
trol group. The prevalence of subclinical atheromatous 
disease in the entire population was significantly higher 
in subjects with prediabetes than in control participants 
(70.4% vs. 67.5%, p = 0.017). This difference was at the 
expense of carotid territory (49.3% vs. 43.5%, p < 0.001), 
and disappeared when only the femoral territory was 
evaluated (54.1% vs. 52.5%, p = 0.228). When each of the 
six specific territories was analyzed in the left and right 
side, slightly marked differences were observed in the 
left arteries (Table  2). In addition, when only women 
were analyzed, the increased prevalence of subclinical 
atheromatous disease detected in postmenopausal con-
trol women when compared to premenopausal control 
women appeared to be attenuated among those with pre-
diabetes (Additional file 1: Table S2).
We observed a significant correlation between 
HbA1c levels and the number of affected territories 
(r = 0.068, p = 0.001), but not with the total plaque area 
(r = − 0.008, p = 0.609). Participants with prediabetes 
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almost increased twice the number of affected territories 
with plaque [2 (1 to 3) vs. 1 (0 to 3) territories, p = 0.002) 
compared with control subjects and, therefore, were 
more likely to be classified as individuals with general-
ized atheromatous disease (19.5% vs. 16.3%, p < 0.001). 
However, the vast majority (82.6%) presented less than 
4 affected territories. In addition, no differences in the 
carotid plaque area (0.22 [0.12;0.42] vs. 0.20 [0.11;0.41], 
p = 0.555), the femoral plaque area (0.68 [0.29;1.24] vs. 
0.68 [0.34;1.18], p = 0.683) or the total plaque area (0.96 
[0.52;1.62] vs. 0.93 [0.56;1.55], p = 0.760) were observed 
between groups.
Table 1 Main clinical, metabolic data, medical treatment and  atheromatous disease characteristics in  the  study 
population according to the presence of prediabetes
Data are expressed as a median [interquartile range] or n (percentage)
HbA1c glycosylated hemoglobin, LDL low density lipoprotein, HDL high density lipoprotein, BP blood pressure, BMI body mass index, CV cardiovascular
a Determination was done in cases in which total cholesterol was ≥ 200 mg/dL and after fasting for 6 h or total cholesterol ≥ 250 mg/dL regardless of fasting hours
b Obesity was defined as a BMI ≥ 30 kg/m2
Prediabetes (n = 2269) Control group (n = 4419) p
Women, n (%) 1290 (56.9) 2151 (48.7) < 0.001
Age (years) 59 [54;64] 57 [52;62] < 0.001
HbA1c (mmol/mol) 40 [39;42] 36 [33;37] < 0.001
HbA1c (%) 5.8 [5.7;6.0] 5.4 [5.2;5.5] < 0.001
Dyslipidemia, n (%) 1290 (56.9) 2214 (50.1) < 0.001
 Total cholesterol (mg/dL) 206 [183;231] 203 [179;229] 0.002
 LDL‑cholesterola (mg/dL) 146 [133;164] 145 [129;162] 0.020
 HDL‑cholesterola (mg/dL) 53 [45;65] 55 [46;67] 0.009
 Triglyceridesa (mg/dL) 148 [113;205] 133 [100;183] < 0.001
 Lipid‑lowering agents, n (%) 534 (23.5) 712 (16.1) < 0.001
 Statins, n (%) 478 (21.0) 656 (14,8) < 0.001
 Fibrates, n (%) 62 (2.7) 54 (1.2) < 0.001
 Ezetimibe, n (%) 8 (0.3) 17 (0.3) 0.838
 Omega‑3 fatty acids, n (%) 6 (0.2) 0 (0.0) 0.001
Hypertension, n (%) 1048 (46.2) 1617 (36.6) < 0.001
 Systolic BP (mm Hg) 132 [120;142] 129 [119;141] < 0.001
 Diastolic BP (mm Hg) 81 [75;88] 81 [75;88] 0.764
 Pulse pressure (mm Hg) 49 [42;58] 47 [40;56] < 0.001
 Antihypertensives, n (%) 911 (40.1) 1305 (29.5) < 0.001
 ACE inhibitors, n (%) 430 (18.9) 659 (14.9) < 0.001
 ARA II, n (%) 230 (10.1) 334 (7.5) < 0.001
 Diuretics, n (%) 441 (19.4) 586 (13.2) < 0.001
 Beta‑blockers, n (%) 196 (8.6) 216 (4.8) < 0.001
 Calcium antagonists, n (%) 147 (6.4) 210 (4.7) 0.003
 Other, n (%) 12 (0.5) 19 (0.4) 0.573
Obesityb, n (%) 817 (36.0) 1176 (26.6) < 0.001
 BMI (kg/m2) 29.6 [26.7;33.1] 28.0 [25.1;31.2] < 0.001
Current or former smoker, n (%) 1211 (53.4) 2714 (61.4) < 0.001
Antithrombotics, n (%) 94 (4.1) 115 (2.6) 0.001
Number of CV risk factors 2 [1;3] 2 [1;2] < 0.001
Characteristics of atheromatous disease
 Presence of any plaque, n (%) 1597 (70.4) 2984 (67.5) 0.017
 Carotid territory affected, n (%) 1112 (49.0) 1924 (43.5) < 0.001
 Femoral territory affected, n (%) 1227 (54.1) 2321 (52.5) 0.228
 Number of affected territories 2 [1;3] 1 [0;3] 0.002
 Total plaque area,  (cm2) 0.96 [0.52;1.62] 0.93 [0.56;1.55] 0.760
 Stenotic lesions ≥ 50% 21 (0.9) 23 (0.5) 0.057
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When the results were assessed according to sex, the 
differences regarding subclinical atheromatous disease 
were greater among males than females (Fig.  1). Men 
with prediabetes presented not only a higher number of 
plaques in both the carotid and femoral regions but also 
an increase of affected territories and total plaque area in 
comparison with age-matched individuals without pre-
diabetes. By contrast, women with prediabetes only pre-
sented a higher number of plaques in the carotid region 
and a similar number of affected territories and total 
plaque area to age-matched women without prediabetes.
In the entire population, the quantity of cardiovascular 
risk factors was correlated with the number of affected 
territories with atheromatous plaque (r = 0.223, p < 0.001) 
and with the total plaque area (r = 0.192, p < 0.001). How-
ever, the presence of prediabetes only impacted on the 
burden of subclinical atheromatous disease when sub-
jects presented three or more CV risk factors (Fig.  2a). 
Notably, when the analysis was performed taking sex into 
account, we observed that men with prediabetes and two 
or more CV risk factors displayed a significantly higher 
number of affected territories with atheromatous plaque 
in comparison with men free of prediabetes (Fig.  2b). 
By contrast, we did not find any significant differences 
between women with prediabetes and the control group 
regardless of the number of CV risk factors (Fig. 2c).
Finally, the multivariable logistic regression model 
showed that smoking habit, male sex, HbA1c, age, sys-
tolic blood pressure, total cholesterol, BMI and lipid-
lowering and antihypertensive drugs were independently 
associated with the presence of atheromatous disease in 
participants with prediabetes (Table 3). When both sexes 
were assessed separately, the same parameters excluding 
HbA1c accounted for subclinical atherosclerosis disease 
in females with prediabetes (Additional file 1: Table S3), 
whereas only smoking status, age and systolic blood pres-
sure were the independent variables in males (Additional 
file 1: Table S4).
Discussion
In the present study we provide evidence that prediabe-
tes modulates the atherogenic effect of cardiovascular 
risk factors in terms of the distribution of plaques and 
the total atherosclerotic burden in a sex-dependent man-
ner. In this regard, our results suggest that prediabetes 
and underlying insulin resistance act as an enhancer of 
the atherosclerotic process, but only in men with 2 or 
more classical CV risk factors. In addition, the distribu-
tion of plaques occurred mainly in the carotid territory 
in women whereas a more severe and widespread plaque 
burden was observed in men.
Cardiovascular disease in prediabetes
The relationship between prediabetes and subclinical 
CV disease has been well-documented [20, 21]. In the 
Heinz Nixdorf Recall Study, a population-based cohort 
of 2184 without overt CV disease from Germany, par-
ticipants with prediabetes (fasting plasma glucose ≥ 6.1 
but < 7.0  mmol/l) showed a higher prevalence of coro-
nary artery calcification than normoglycemic partici-
pants [20]. However, the association between impaired 
fasting glucose and coronary artery calcification was less 
pronounced in women [20]. In the Multi-Ethnic Study of 
Atherosclerosis, a cross-sectional study among 5121 par-
ticipants without type 2 diabetes or CV disease, those in 
the highest quartile of HbA1c showed significantly higher 
values for common and internal carotid intimal-medial 
wall thickness in both sexes, but the association between 
HbA1c and carotid artery calcification was only present 
in women [21]. On the other hand, in a recent study with 
6434 asymptomatic Korean individuals who underwent 
a coronary computed tomographic angiography, predia-
betes was not associated with an increased risk of sub-
clinical coronary atherosclerosis [22]. Our study adds 
information by providing the characteristics of the ath-
eromatous process in a population of middle-aged sub-
jects without previous vascular disease according to the 
presence of prediabetes. We describe how subjects with 
prediabetes suffer a higher prevalence of atheromatous 
disease, mainly in the carotid territories, when compared 
with subjects with normal HbA1c. In addition, vascular 
disease in participants with prediabetes is characterized 
by the presence of plaques of a similar area in a higher 
Table 2 Prevalence of  subclinical atheromatous disease 
in  each of  the  six specific territories in  left and  right 
arteries according to the presence of prediabetes
Data are expressed as a median [interquartile range] or n (percentage)
Prediabetes 
(n = 2269)
Control 
group 
(n = 4419)
p
Left arteries 1297 (57.2) 2395 (54.2) 0.021
 Common carotid artery, n (%) 95 (4.2) 142 (3.2) 0.041
 Bifurcation carotid artery, n (%) 644 (28.4) 1118 (25.3) 0.018
 Internal carotid artery, n (%) 350 (15.4) 546 (12.3) 0.002
 External carotid artery, n (%) 31 (1.4) 69 (1.6) 0.534
 Common femoral artery, n (%) 925 (40.8) 1775 (40.2) 0.636
 Superficial femoral artery, n (%) 152 (6.7) 232 (5.3) 0.016
Right arteries 1348 (59.4) 2513 (56.9) 0.046
 Common carotid artery, n (%) 68 (3.0) 129 (2.9) 0.376
 Bifurcation carotid artery, n (%) 659 (29.1) 1053 (23.8) < 0.001
 Internal carotid artery, n (%) 322 (14.2) 578 (13.1) 0.240
 External carotid artery, n (%) 40 (1.8) 78 (1.8) 0.992
 Common femoral artery, n (%) 1018 (44.9) 1936 (43.8) 0.411
 Superficial femoral artery, n (%) 172 (7.6) 275 (6.2) 0.035
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Fig. 1 Atheromatous disease characteristics in the; a men and b women. Data are expressed as a median [interquartile range] or n (percentage)
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Fig. 2 Plot displaying the number of affected territories with atheromatous plaque according to the quantity of cardiovascular risk factors such as 
dyslipidemia, blood hypertension, obesity, smoking habit or a first degree relative with premature cardiovascular disease in the; a entire population, 
b men and c women
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number of affected territories. Overall, our data reinforce 
the idea that CV disease is a progressive defect associated 
with glucose abnormalities, appearing and increasing 
throughout the prediabetes stage. In fact, in the subjects 
with prediabetes, HbA1c positively correlates with the 
number of plaques. However, it should be noted that in 
the population included in our study the total plaque area 
was similar to age-matched control subjects. In addi-
tion, prediabetes was only a trigger for the number of 
affected territories when at least 3 classic CV risk factors 
were present. These findings seriously call into question 
the importance of insulin resistance and the prediabetes 
stage as primary factors of atherogenesis in the type 2 
diabetes population. The lack of significance of the waist 
circumference in the multivariable logistic regression 
model in both sexes also argues against this assumption. 
In the Coronary Artery Risk Development in Young Adults 
Study, for each 5-year-long duration of prediabetes the 
hazard ratio for the presence of coronary artery calcified 
plaque was only 1.07 (1.01 to 1.13) [23]. This result also 
supports the modest effect of prediabetes itself as a CV 
risk factor.
The different impact of prediabetes on atherosclerotic 
processes in men and women merits some comment. 
First, it has been suggested that men and women may 
progress from normoglycemia to overt type 2 diabetes 
by different ways: more men than women had impaired 
fasting glucose, whereas women more often had impaired 
glucose tolerance [24]. Also, in the Framingham Heart 
Study, the 4-year coronary heart disease event rate 
among participants with prediabetes differed accord-
ing to the prediabetes definition and the participants’ 
sex [25]. Whether or not the different transitional stage 
from normoglycemia to diabetes has a differential effect 
in the atherogenic process is an issue that remains to be 
elucidated. Second, the relative contribution of ageing 
and menopause itself in the development of CV diseases 
still remains uncertain [26]. It should be noted that the 
youngest women recruited in the LERVAS cohort were 
50 years old. Therefore, the relative protection of women 
against prediabetes-induced plaque formation seems to 
be unrelated with estrogen levels. However, the inher-
ent difference in circulating testosterone levels between 
men and women could not be ruled out as an underlying 
mechanism accounting for the widespread and signifi-
cantly greater plaque detected in men [27].
The predilection of prediabetes for the carotid territory 
deserves attention, particularly when its impact in CV 
disease may be markedly different. In an autopsy study, 
Dalager et  al. described different features in the micro-
scopic sections of the carotid and superficial femoral 
arteries, probably reflecting different formation pathways 
[28]. Unlike the femoral arteries, the carotid bifurcation 
was prone to foam cell lesions and plaque formation, 
and lipid core plaques were more much common in the 
carotid territory in samples from patients who died of 
coronary atherosclerosis [28]. Similarly, in  vivo non-
invasive magnetic resonance plaque-imaging visual-
ized significant differences in plaque composition, with 
larger necrotic cores as well as hemorrhaged areas in the 
carotid arteries compared to the femoral arteries [29]. 
And in clinical practice, the significant correlation found 
between the stenosis of coronary segments and carotid 
plaque occurrence disappeared when femoral plaques 
were evaluated [30]. Therefore, carotid territories are 
more prone to develop complicated plaques than femoral 
arteries, thus explaining different rates in the progression 
of atherosclerotic disease and the outcomes of CV events 
in subjects with prediabetes [11, 31]. In this way, results 
from the Emerging Risk Factors Collaboration revealed 
that the risk of stroke in patients with diabetes mellitus 
Table 3 The multivariable logistic regression model 
for  presence of  atheromatous disease in  subjects 
in the prediabetes stage
a High waist circumference was defined as ≥ 102 cm for men and ≥ 88 cm for 
women
Odds ratio (95% 
confidence interval)
p
Sex
 Women Ref.
 Men 3.37 (2.60 to 4.36) < 0.001
Age (years) 1.10 (1.07 to 1.12) < 0.001
Glycosylated hemoglobin (%) 1.92 (1.09 to 3.38) 0.024
Total cholesterol (mg/dL) 1.01 (1.01 to 1.01) < 0.001
Lipid‑lowering agents
 No Ref.
 Yes 0.64 (0.50 to 0.83) 0.001
Systolic blood pressure (mm Hg) 1.01 (1.01 to 1.02) < 0.001
Antihypertensive treatment
 No Ref.
 Yes 0.77 (0.62 to 0.96) 0.018
Body mass index (kg/m2) 0.99 (0.96 to 1.01) 0.234
Waist  circumferencea
 Normal Ref.
 High 1.05 (0.77 to 1.42) 0.762
Smoking status
 Never Ref.
 Former 1.89 (1.49 to 2.41) < 0.001
 Current 5.23 (3.85 to 7.11) < 0.001
Antithrombotic treatment
 No Ref.
 Yes 0.82 (0.46 to 1.45) 0.491
Test of fit Hosmer–Lemeshow 0.586
Area under de ROC curve 0.74 (0.72 to 0.76) < 0.001
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is increased twofold compared with individuals without 
diabetes mellitus [32]; the risk of recurrent stroke is also 
increased [33]. Prediabetes (defined as impaired glucose 
tolerance or a combination of impaired fasting glucose 
plus impaired glucose tolerance) has also been associ-
ated with a higher future risk of stroke (relative risk 1.20, 
95% confidence interval 1.07 to 1.35) [34]. The 10-year 
planned follow-up of the ILERVAS Project will give us 
relevant clinical information on this topic [13].
Prediabetes duration has been associated with subclini-
cal atherosclerosis, suggesting that prevention strategies 
to reverse cumulative exposure to this metabolic transi-
tion stage are needed [35]. From the global 374 million 
people with prediabetes in 2017, only 1.95% will progress 
to type 2 diabetes per year, suggesting that a substantial 
number of subjects will continue unprotected against 
long-term intermediate glycemic elevations [1, 36]. Our 
results suggest that men with at least 2 traditional risk 
factors represent the target prediabetes sub-population 
in which the efforts for testing the protective effects 
of anti-atherogenic therapeutic strategies should be 
addressed.
Potential pathogenic mechanisms
The mechanisms which explain the burden of arterial 
plaque associated with prediabetes, and their impact on 
different arterial territories, are not yet fully understood. 
The role of hemodynamic features and the underlying 
blood vessel structure warrants attention, since vascu-
lar anatomy is not uniform for the thickness of intima-
media layer and the left carotid artery originates directly 
from the aortic arch and is therefore exposed to a con-
stantly higher shear stress [37, 38]. In contrast to the 
femoral artery, a transitional zone has been described in 
the carotid bifurcation, an artery segment between elas-
tic and muscular cell types where foam cell lesions and 
lipid core plaque develop at early ages [28, 39]. In addi-
tion, in  vivo magnetic resonance imaging studies have 
described how the decrease of the lumen area by femo-
ral plaque progression is compensated for by positive 
remodeling, creating a dissimilar rate of progression of 
luminal stenosis between the carotid and femoral arter-
ies [40]. The impact of metabolic changes associated with 
prediabetes in these selected segments, such as insulin 
resistance, low-grade chronic inflammation, advanced 
glycation end-products (AGEs) production, dyslipi-
demia or fibrinolytic dysfunction, in the carotid transi-
tional zone or in arterial remodeling is unclear [41–44]. 
The concentration of the endogenous secretory receptor 
for the AGEs receptor in 220 patients with prediabetes 
was significantly lower than in 99 control subjects and 
was one of the main determinants of the intima-media 
thickness of the common carotid artery [42]. Similarly, 
insulin resistance indices were strongly related to carotid 
intima-media thickness, and plaque presence and area 
in patients without diabetes, but were without relevance 
when femoral atherosclerosis was evaluated [41]. More 
recently, Altin et  al. [43] showed how common carotid, 
but not femoral, intima media thickness was significantly 
higher in 113 patients with insulin resistance (homeo-
stasis model assessment index > 2.5) free of CV disease 
compared to 112 controls. In our population without 
previous CV events, male participants with prediabetes 
exhibited a higher prevalence of atheromatous plaque 
both in carotid and femoral territories in comparison 
with the control group. However, women with predia-
betes only presented a higher number of plaques in the 
carotid region. These findings reinforce the rationale of 
selecting the carotid territory for performing a screen-
ing of subclinical CV disease in those subjects with 
prediabetes.
Limitations and strengths
This study has some limitations that need to be consid-
ered. First, it is a cross-sectional analysis, so the nature of 
the study has not allowed us to establish causality. How-
ever, we will be doing a follow-up of the entire popula-
tion until 2028. Second, the three accepted prediabetes 
definitions according to the criteria of the American Dia-
betes Association seem to identify different populations, 
as often not all the tests identify prediabetes in the same 
individual [14, 45, 46]. Some advantages have been linked 
to HbA1c, such as that fasting is not required, and the 
nonappearance of daily alterations in periods of illness or 
stress, and its higher preanalytical stability [20]. In addi-
tion, the prediabetes HbA1c-based definitions appears to 
be more specific and to provide modest improvements 
in risk discrimination for CV disease and other clinical 
complications than definitions based on fasting plasma 
glucose [47]. Third, although we have tested HbA1c using 
a point-of-care instrument, the large population included 
in our study allowed us to define two well differentiated 
populations, not only in their HbA1c values but also in 
their anthropometric and clinical characteristics. In addi-
tion, we have no available data regarding the duration of 
prediabetes in our population. Finally, LDL-cholesterol 
was assessed regardless of the fasting state when total 
cholesterol was ≥ 200  mg/dl or only after 6  h of fasting 
when ≥ 250 mg/dl, what it is not the standard recommen-
dation. However, it is not very far from the recent new 
lipid guidelines that summarizes that in adults ≥ 20 years 
old and not on lipid-lowering therapy (the 80.7% of our 
population), measurement of either fasting or a non-fast-
ing lipid profile is effective in estimating atherosclerotic 
cardiovascular disease risk and recording baseline LDL-
cholesterol [48].
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Conclusions
In summary, prediabetes is associated with a significantly 
increased burden of atheromatous disease in men with 
2 or more CV risk factors. This finding points to this 
subpopulation as the main target for strategies aimed at 
reducing CV risk factors and HbA1c. In addition, our 
results suggest that the global impact of prediabetes on 
the atherosclerotic process in the entire population is 
quite limited.
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